Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates

被引：2
|
作者：
Kilgour, E. [1 ]
Angell, H. [2 ]
Smith, N. R. [1 ]
Ahdesmaki, M. [2 ]
Barrett, J. C. [3 ]
Harrington, E. A. [2 ]
Hurst, C. [4 ]
Knowles, M. A. [4 ]
机构：
[1] AstraZeneca, Oncol Translat Sci, Macclesfield, Cheshire, England
[2] AstraZeneca, Oncol Translat Sci, Cambridge, England
[3] AstraZeneca, Oncol Translat Sci, Boston, MA USA
[4] Univ Leeds, Inst Canc & Pathol, Leeds, W Yorkshire, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw373.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
786P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
    Young Saing Kim
    Kyung Kim
    Ghee-Young Kwon
    Su Jin Lee
    Se Hoon Park
    BMC Urology, 18
  • [2] Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
    Kim, Young Saing
    Lee, Soon Il
    Park, Se Hoon
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
    Kim, Young Saing
    Kim, Kyung
    Kwon, Ghee-Young
    Lee, Su Jin
    Park, Se Hoon
    BMC UROLOGY, 2018, 18
  • [4] Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
    Pouessel, D.
    Neuzillet, Y.
    Mertens, L. S.
    van der Heijden, M. S.
    de Jong, J.
    Sanders, J.
    Peters, D.
    Leroy, K.
    Manceau, A.
    Maille, P.
    Soyeux, P.
    Moktefi, A.
    Semprez, F.
    Vordos, D.
    de la Taille, A.
    Hurst, C. D.
    Tomlinson, D. C.
    Harnden, P.
    Bostrom, P. J.
    Mirtti, T.
    Horenblas, S.
    Loriot, Y.
    Houede, N.
    Chevreau, C.
    Beuzeboc, P.
    Shariat, S. F.
    Sagalowsky, A. I.
    Ashfaq, R.
    Burger, M.
    Jewett, M. A. S.
    Zlotta, A. R.
    Broeks, A.
    Bapat, B.
    Knowles, M. A.
    Lotan, Y.
    van der Kwast, T. H.
    Culine, S.
    Allory, Y.
    van Rhijn, B. W. G.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1311 - 1316
  • [5] The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate
    van Rhijn, BWG
    Lurkin, I
    Radvanyi, F
    Kirkels, WJ
    van der Kwast, TH
    Zwarthoff, EC
    CANCER RESEARCH, 2001, 61 (04) : 1265 - 1268
  • [6] Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas
    Larson, Andrew
    Cook, James R.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2008, 16 (04) : 322 - 325
  • [7] The accumulation of mutant fibroblast growth factor receptor 3 (FGFR3) in the endoplasmic reticulum of chondrocytic cells and their apoptosis
    Nasu, M
    Amizuka, N
    Li, M
    Nomura, S
    Henderson, JE
    Maeda, T
    BONE, 2005, 36 : S175 - S175
  • [8] MAb Against Fibroblast Growth Factor Receptor 3 (Mutant FGFR3/S249C)
    Filonenko, Valeriy
    HYBRIDOMA, 2009, 28 (04): : 301 - 301
  • [9] FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer
    Neuzillet, Yann
    van Rhijn, Bas W. G.
    Prigoda, Nadia L.
    Bapat, Bharati
    Liu, Liyang
    Bostrom, Peter J.
    Fleshner, Neil E.
    Gallie, Brenda L.
    Zlotta, Alexandre R.
    Jewett, Michael A. S.
    van der Kwast, Theo H.
    VIRCHOWS ARCHIV, 2014, 465 (02) : 207 - 213
  • [10] Fibroblast growth factor receptor 3 (FGFR3) mutation in an extensive epidermal naevus
    Collin, B.
    Taylor, I. B.
    Wilkie, A. C. M.
    Moss, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 : 8 - 9
12345